Coach — Methylene Blue (Strength / ETC+)
It began as a coal-tar dye. It may be best understood as a courier, ferrying electrons past a jam, and like any courier it works only at the right pace.
Methylene blue began as a coal-tar dye. In 1876 Heinrich Caro, working at the firm that became BASF, oxidized an aniline compound and produced a brilliant blue for cotton. Within fifteen years it had left the dye works for the clinic. In 1891 Paul Ehrlich and Paul Guttmann gave it to malaria patients; the parasites were stained and immobilized, and the fever receded. It was the first fully synthetic molecule given deliberately as a medicine. Robert Koch used it to make the tuberculosis bacterium visible. Santiago Ramón y Cajal used it as a living stain for neurons. By the 1930s William Wendel had shown that it reliably reverses methemoglobinemia, a condition in which blood loses its ability to carry oxygen. It became the ancestor of an entire class of psychiatric drugs, the phenothiazines.
Then it nearly vanished. Cheaper patentable antimalarials and, later, receptor-targeted drugs took over, and methylene blue was demoted to emergency antidote and surgical stain. Its virtues, extreme cheapness, no patent, chemical simplicity, a mechanism that binds no fashionable receptor, made it commercially uninteresting. When wellness culture rediscovered it, blue tongues and influencer videos invited ridicule. Large Alzheimer's trials of improved versions of the molecule missed their main goals. The safety warnings are real. Yet the mockery tends to stop at the surface: a dye, therefore unserious; old, therefore obsolete; cheap, therefore unlikely to work.
The metabolic reading is different.
The courier
Inside every mitochondrion runs a chain of protein complexes that passes electrons from food toward oxygen, pumping protons as it goes and using that pressure to make ATP, the body's energy currency. When the early stations of the chain, called Complex I and Complex III, are damaged or congested, electrons pile up and leak, forming reactive oxygen species instead of energy.
Methylene blue can act as a courier around that jam. Its chemistry places it, electrically speaking, between the starting point of the chain and a later carrier called cytochrome c. At low concentrations it picks up electrons near the start and hands them directly to cytochrome c, skipping the congested middle. Complex IV keeps pumping, the proton pressure is maintained, and ATP production continues. Leak falls. The dye cycles between a blue form and a colorless form, which is why a little goes a long way: it is catalytic, not consumed.
The detour has secondary effects. By clearing a backlog of NADH, a key electron carrier, it relieves a brake on the central energy cycle and supports enzymes that depend on its partner, NAD, including the sirtuins involved in cellular quality control. It also has other pharmacology, mild effects on the enzyme that breaks down serotonin, on nitric oxide, on the tau protein, on cellular cleanup, that may matter in some settings. In this hypothesis they stay secondary. The lead story is coherent electron flow.
The pace matters
Every courier has a right speed. Methylene blue's dose-response follows a classic inverted U, rooted in its chemistry. At low local concentrations it cycles productively and helps the chain. At high concentrations the balance tips: it pulls electrons away from the chain, increases radical production, inhibits respiration, and in the blood promotes the very methemoglobin it treats at proper doses. In one line of rat brain studies, activity of the final enzyme in the chain peaked near half a micromolar and was back at or below baseline by five. The same shape appears across measures of oxygen use, ATP, memory, and neuroprotection. The real question is not whether a beneficial window exists. It is which exposures stay on its productive side.
What has actually been shown
In isolated mitochondria and cultured cells, the effects are robust. Methylene blue raises oxygen use even when Complex I or Complex III is chemically blocked, raises ATP, reduces reliance on glycolysis, and protects cells from a range of energy insults. In animals, low doses improve memory retention, protect against stroke-like and traumatic brain injury, and reduce damage in models of Parkinson's and Alzheimer's disease. It combines with near-infrared light, which also acts on the chain's final enzyme, for added effect. The protection disappears when the dye's electron-carrying center is chemically disabled, which suggests the courier role is doing the work.
In people, the only approved use is methemoglobinemia, treated intravenously at one to two milligrams per kilogram. Established off-label uses include a severe form of shock and a drug-induced brain toxicity, and surgeons use it routinely as a stain. The cognitive evidence is smaller. In a randomized, placebo-controlled brain-imaging study of twenty-six healthy adults, a single oral dose of 280 milligrams, about four milligrams per kilogram, increased activity in memory-related brain regions and improved correct memory retrieval by seven percent. In bipolar disorder, a crossover trial of adjunct methylene blue, comparing 195 milligrams with a 15-milligram comparison dose, improved lingering depression and anxiety without provoking mania. Trials of a single intravenous dose of two milligrams per kilogram around surgery reduced postoperative delirium in older patients.
The Alzheimer's programs are the sobering counterweight. Large late-stage trials of improved derivatives missed their primary endpoints, though analyses of subgroups are still debated, and an eight-milligram-a-day comparison arm keeps reappearing as a possible signal. Those failures say something about treating advanced disease and about dose and formulation. They do not erase the mechanism. They do caution against assuming that more milligrams of a dye will melt a late-stage brain disease.
Three windows, not one number
Much confusion comes from collapsing three different exposure ranges into a single "dose." This hypothesis keeps them apart, and none of them is a recommendation.
Window A is the lowest. It is the range discussed in this hypothesis for supporting the electron transport chain over time: amounts on the order of eight to twenty-five milligrams. That is information about the hypothesis, not advice; any use is physician-guided.
Window B is the low therapeutic range used in published studies for specific indications: roughly half a milligram to four milligrams per kilogram, often as a single dose or a short course, as in the memory, mood, and surgical studies above. Those exposures were often still on the beneficial side of the curve. They are study amounts, not a daily target, and climbing toward them raises the serotonin-syndrome concern.
Window C is the high, oxidative range, where the courier turns saboteur: net oxidant effects, respiratory inhibition, methemoglobin risk. In this hypothesis it begins clinically somewhere above five to ten milligrams per kilogram, or with repeated high oral exposure. It is the far side of the curve, and it is to be avoided.
Hard stops
Enthusiasm meets several walls. Methylene blue carries an FDA boxed warning for serotonin syndrome with SSRIs, SNRIs, MAOIs and other serotonergic drugs, and it is avoided in G6PD deficiency and pregnancy; any use belongs with your own physician. G6PD deficiency is an absolute contraindication because of the risk of destroying red blood cells. Serotonergic drugs, including SSRIs and MAO inhibitors, create a real risk of serotonin syndrome that rises with dose; that question belongs with a physician, never with a shopping cart. Pregnancy and other clinical red flags belong in the same screen, and the go/no-go there is a physician’s call too. Purity is non-negotiable: aquarium, laboratory, and industrial grades can carry heavy metals, and only pharmaceutical-grade material should ever be considered. High doses invert the effect. Chronic high-dose oral use in healthy people lacks large, long-term safety data. Even at low amounts, loose stools are common when oral dye first reaches the gut, probably a local effect on the intestinal lining and flora; persistent watery or cramping diarrhea is a reason to stop and involve a physician, not to experiment.
If those gates are not cleared, the tool stays on the shelf, and the right move is to build the foundation instead.
Timing and the training signal
Hard exercise generates controlled bursts of reactive oxygen, much of it from enzymes outside the mitochondrial chain, and those bursts help drive adaptation. Methylene blue is not a megadose of vitamin C or E, and it does not abolish that signal. Morning timing was used in some cognitive studies, where scans followed an hour after the dose. That is study geometry, not an instruction. Plasma levels peak within one to two hours and fall over several half-lives, while tissue levels linger longer.
A courier, not the road
In the larger framework of this site, methylene blue belongs with strength, not fuel. It is not food. It is a tool aimed at the machinery, a possible complement to creatine, to the NAD-supporting nutrients, and to red and near-infrared light, which reach the same final enzyme by physical rather than chemical means. And it is downstream of everything else. Do not reach for it while the diet still runs on sugar, seed oils, and habitual alcohol and the days and nights are in chaos. Do not cast it as a brain drug while sleep, light, and training go untouched. Do not import study-range doses into a daily routine because a single study once used them. Do not call aquarium dye frugal medicine.
The oldest synthetic drug still works by the most fundamental principle of aerobic life, the orderly passage of electrons from food to oxygen. When that passage becomes disordered, a nineteenth-century dye offers a cheap, catalytic detour. Whether it belongs in any particular life is a question for a physician. That it deserves to be taken seriously, in hypothesis, and at the low end of its curve, is the argument. Frugal here means cheap and pharmaceutical-grade, after the road itself has been repaired.
For the full mechanism and literature, read the extended report on methylene blue. A short version lives at Methylene blue in brief, and other essays are collected on the essay index.
A working hypothesis, open to correction and revised as new evidence arrives. Last revised October 17, 2026.
See the notice at the top of this page. Working hypothesis, not medical advice.
Related: Methylene blue on Surf Shop (sold through MDVite, EnSurf LLC’s store).
Related: Coach — The Tau Loop (brain and neurodegeneration).
Related: Coach — Dry Eye and the Ocular Surface (Wipeouts · Ophthalmology).
Related: Coach — Fuchs’ Dystrophy (Wipeouts · Ophthalmology).